# Twist Bioscience Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Twist Bioscience Corp). ## Overview Twist Bioscience Corp is a U.S.-based synthetic biology company that manufactures synthetic DNA and related life-science products using a proprietary silicon-based DNA writing platform. Its offerings support customers in healthcare, academic research, food and agriculture, and industrial applications, with sales made through direct channels, distributors, and an e-commerce platform. ## Products & services • Synthetic genes • Oligo pools and DNA libraries • NGS tools / NGS applications • Antibody discovery and optimization services • Protein solutions and biologics discovery services - **NGS tools / NGS applications** (55%) — Products and workflows used in next-generation sequencing and DNA reading applications. - **Synthetic genes** (30%) — Custom DNA sequences manufactured for research, discovery, and engineering biology. - **Oligo pools** (6%) — Massively parallel oligonucleotide libraries used in screening and research workflows. - **Antibody discovery** (6%) — Biopharma services for antibody discovery, optimization, and development. - **DNA libraries** (3%) — Prepared DNA libraries used in sequencing, screening, and research applications. - Synthetic genes - Oligo pools and DNA libraries - NGS tools / NGS applications - Antibody discovery and optimization services - Protein solutions and biologics discovery services ## Customers Twist sells to a broad base of more than 3,800 customers across healthcare, academic research, industrial, and food/agriculture end markets. Buyers include biopharma and biotech teams, research institutions, and industrial R&D groups that need custom DNA, sequencing tools, or discovery services to accelerate experiments and product development. - **Healthcare / biopharma** (primary) — Buys synthetic DNA, antibody discovery, and protein-related services for therapeutic research and development. - **Academic research** (primary) — Buys custom DNA, libraries, and sequencing tools for discovery, validation, and education. - **Industrial chemicals/materials** (secondary) — Buys DNA-based products to support engineering of specialty chemicals and materials. - **Food and agriculture** (secondary) — Buys synthetic biology tools for crop improvement and agricultural R&D. - **NGS users** (primary) — Buys NGS tools and applications for sequencing workflows and sample preparation. - Biopharma and biotech customers buying DNA and discovery services - Academic researchers using synthetic DNA for experiments and education - Industrial R&D teams developing chemicals, materials, and specialty products - Food and agriculture customers working on crop and trait development - NGS users needing sequencing-related tools and sample prep products ## Geography Twist sells globally, with revenues reported across the Americas, EMEA, and APAC. The Americas are the largest region, while EMEA is a meaningful second market and APAC contributes a smaller but important share of demand; the company also uses commercial consultants in Europe and Asia to support local selling. - **Americas** (60%) — Includes United States, Canada, Mexico and South America - **EMEA** (33%) — Includes Europe, Middle East and Africa - **APAC** (7%) — Includes Japan, China, South Korea, India, Singapore, Malaysia, Australia, New Zealand, Thailand and Taiwan - Americas accounted for 60% of revenue in fiscal 2025 - EMEA accounted for 33% of revenue in fiscal 2025 - APAC accounted for 7% of revenue in fiscal 2025 - Commercial consultants support sales in Europe and Asia - Revenue is based on customer shipping addresses ## Strategy Twist’s strategy centers on scaling its silicon-based DNA synthesis platform across more product lines and end markets. It also emphasizes a multi-channel commercial model, combining direct sales, e-commerce, and regional consultants to reach a large and fragmented customer base. - **Expand platform breadth** (medium-term) — A wider product set increases customer wallet share and cross-selling across research workflows. - **Scale digital and direct sales channels** (short-term) — The customer base is broad and fragmented, so efficient ordering and support improve reach and retention. - **Increase biopharma and healthcare penetration** (medium-term) — These end markets can use multiple Twist products and services across discovery workflows. - Expand the synthetic DNA platform into adjacent products and services - Grow NGS applications and protein-related offerings - Use e-commerce to serve high-volume, repeat customers efficiently - Deepen penetration in healthcare and biopharma discovery workflows - Broaden global commercial reach through direct sales and regional support ## Risks Twist depends heavily on proprietary DNA synthesis technology, so intellectual property protection, biosecurity compliance, and product misuse are central risks. It also faces customer concentration, competitive pressure, and execution risk as it tries to grow across multiple end markets and geographies. - **Intellectual property protection** [high] — The business depends on proprietary synthesis methods and software that competitors could attempt to copy or design around. - **Biosecurity and regulatory compliance** [high] — DNA synthesis is subject to biosafety and biosecurity rules that can limit what sequences can be produced and how orders are screened. - **Customer concentration and retention** [medium] — Revenue can be affected if a limited number of large customers reduce orders or switch suppliers. - **Competitive pressure** [medium] — The company operates in a technically demanding market where rivals can compete on price, speed, and service. - **Reputational risk from product use** [medium] — Customers may use DNA products in ways that attract scrutiny or damage trust in the platform. - IP protection is critical to defend the silicon-based DNA platform - Biosecurity rules can restrict certain DNA synthesis activities - A limited number of large customers can affect revenue stability - Competition may pressure pricing and customer retention - Third-party misuse of products can create reputational and legal risk ## Accounting Twist’s reporting is shaped by revenue recognition across multiple product and service lines, including direct product sales and biopharma services. Investors should also watch estimates tied to long-lived assets, impairment, and the accounting for gains or proceeds from business sales, since these can materially affect reported results. - **Revenue recognition** — Reported revenue mix and timing - **Long-lived asset impairment** — Operating results and asset carrying values - **Gain on sale of business** — Net income and comparability - **Estimates and judgments** — Balance sheet and earnings volatility - Revenue recognition across product and service offerings - Quarterly seasonality and mix shifts across end markets - Impairment testing for long-lived assets and other assets - Accounting for gains on business sales and related proceeds - Estimates and judgments in valuation and reserves --- *Last updated: 2026-04-29T05:04:52.407736+00:00*